EUVIMEDEUVIMED entdecken
Crossref

Lansbermin‐I : A Snake Venom Disintegrin With Selective Cytotoxicity and Anti‐Adhesive Effects Against Glioblastoma Cells

Javier Orozco-Mera iD, Alejandro Montoya-Gómez iD, María José Sevilla-Sánchez iD, Ana María Arboleda Borrero iD, Mildrey Mosquera Escudero iD, Eliécer Jiménez-Charris iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Javier Orozco-Mera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Valle de Cauca, Colombia. Hauptthemen laut MEDLINE: Glioblastoma, Disintegrins, Antineoplastic Agents, Brain Neoplasms. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is the most common and aggressive malignant brain tumor, characterized by poor response to current therapies and inevitable recurrence. Novel therapeutic strategies are urgently needed. Lansbermin‐I , a disintegrin isolated from the venom of Porthidium lansbergii lansbergii , was purified, sequenced, structurally modeled, and evaluated for its antitumor potential against the human Glioblastoma cell line T98G. Cytotoxicity assays revealed a dose‐dependent effect, with Lansbermin‐I inducing up to 38.1% cell death at 100 μg/mL, surpassing the activity of temozolomide (34.9%) while exhibiting lower toxicity on non‐tumorigenic human astrocytes (28% vs. 37%). Lansbermin‐I also inhibited T98G adhesion to fibronectin by nearly 80% ( p < 0.0001), suggesting interference with integrin‐mediated interactions. Flow cytometry demonstrated a significant increase in apoptotic cells (60% vs. 36% in control) and cell cycle arrest at the G1 phase. In silico docking studies supported a strong interaction of Lansbermin‐I with integrin αvβ3, comparable to that of fibronectin, reinforcing its potential mechanism of action through the disruption of adhesion and survival signaling. Collectively, these findings highlight Lansbermin‐I as a promising selective prototype for Glioblastoma therapy. Further studies are warranted to elucidate its molecular targets and evaluate its efficacy in preclinical models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDisintegrinsAntineoplastic AgentsBrain NeoplasmsSnake VenomsHumansCell Line, TumorCell AdhesionApoptosisAnimalsMolecular Docking SimulationFibronectinsIntegrin alphaVbeta3

Stichwörter der Autor:innen

Porthidium lansbergii lansbergiianticancer moleculesbioprospectingbrain cancerdisintegrinmolecular docking

Substanzen

DisintegrinsAntineoplastic AgentsSnake VenomsFibronectinsIntegrin alphaVbeta3

Autor:innen und Institutionen

  • Grupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Valle de Cauca, Colombia.
  • Department of Neurosurgery, Clínica Imbanaco, Cali, Valle del Cauca, Colombia.

ORCID-Profile: Javier Orozco-Mera, Alejandro Montoya-Gómez, María José Sevilla-Sánchez, Ana María Arboleda Borrero, Mildrey Mosquera Escudero, Eliécer Jiménez-Charris

Zitieren

APA

Orozco-Mera, J., Montoya-Gómez, A., Sevilla-Sánchez, M. J., Borrero, A. M. A., Escudero, M. M., & Jiménez-Charris, E. (2026). Lansbermin‐I : A Snake Venom Disintegrin With Selective Cytotoxicity and Anti‐Adhesive Effects Against Glioblastoma Cells. Drug Development Research. https://doi.org/10.1002/ddr.70218

Vancouver

Orozco-Mera J, Montoya-Gómez A, Sevilla-Sánchez MJ, Borrero AMA, Escudero MM, Jiménez-Charris E. Lansbermin‐I : A Snake Venom Disintegrin With Selective Cytotoxicity and Anti‐Adhesive Effects Against Glioblastoma Cells. Drug Development Research. 2026. doi:10.1002/ddr.70218

BibTeX
@article{OrozcoMera2026,
  author = {Orozco-Mera, Javier and Montoya-Gómez, Alejandro and Sevilla-Sánchez, María José and Borrero, Ana María Arboleda and Escudero, Mildrey Mosquera and Jiménez-Charris, Eliécer},
  title = {Lansbermin‐I : A Snake Venom Disintegrin With Selective Cytotoxicity and Anti‐Adhesive Effects Against Glioblastoma Cells},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70218}
}
Kostenlos starten →